File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3- gallate on the growth of androgen-independent prostate cancer in vivo

TitleEffect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3- gallate on the growth of androgen-independent prostate cancer in vivo
Authors
Issue Date2008
PublisherLawrence Erlbaum Associates, Inc. The Journal's web site is located at http://www.leaonline.com/loi/nc
Citation
Nutrition And Cancer, 2008, v. 60 n. 4, p. 483-491 How to Cite?
AbstractEpigallocatechin-3-gallate (EGCG) is the major and most potent polyphenol compound of green tea that has been shown to have anticancer effects against various types of cancers. In this study, in addition to the EGCG compound, a synthetic derivative, the peracetate of EGCG (EGCG-P), was used to investigate the inhibitory effects on growth of androgen-independent prostate cancer in vivo. The advantage of EGCG-P is that it may act as a prodrug, leading to higher bioavailability than EGCG itself. The aim of our study was to compare the differences between EGCG and EGCG-P on their inhibitory effect on androgen-independent prostate cancer, CWR22R, xenograft model in nude mice. The mice were administrated daily with solvent dimethyl sulfoxide, EGCG, and EGCG-P separately through intraperitoneal injection for 20 days. Tumor volume and body weight of nude mice were recorded daily. Serum prostate-specific antigen (PSA) levels were also measured before and after the treatment. The effects of both EGCG and EGCG-P on tumor cell proliferation were assessed by immunohistochemical (IHC) method using antibodies against Ki-67 and proliferating cell nuclear antigen. The apoptotic effect was evaluated by IHC against B-cell non-Hodgkin lymphoma-2 and terminal deoxynucleotidyl transferase dUTP nick-end labeling assay by in situ apoptosis detection kit. Moreover, the potential suppression of angiogenesis by EGCG and EGCG-P on prostate cancer was examined by IHC against CD31. Our results revealed that treatment of EGCG and EGCG-P compounds suppressed the growth of CWR22R xenografts without causing any detectable side effects in nude mice. The suppression of growth of the tumor was correlated with the decrease of serum PSA level together with the reduction in tumor angiogenesis and an increase in apoptosis on prostate cancer cells. The results showed that treatment of EGCG and EGCG-P inhibited tumor growth and angiogenesis while promoting apoptosis of the prostate cancer cells in vivo. Our results suggest that EGCG-P may be a more stable and useful compound for increasing the therapeutic anticancer effects in androgen-independent prostate cancer. Copyright © 2008, Taylor & Francis Group, LLC.
Persistent Identifierhttp://hdl.handle.net/10722/149697
ISSN
2015 Impact Factor: 2.241
2015 SCImago Journal Rankings: 0.931
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLee, SCen_US
dc.contributor.authorChan, WKen_US
dc.contributor.authorLee, TWen_US
dc.contributor.authorLam, WHen_US
dc.contributor.authorWang, Xen_US
dc.contributor.authorChan, THen_US
dc.contributor.authorWong, YCen_US
dc.date.accessioned2012-06-26T05:57:14Z-
dc.date.available2012-06-26T05:57:14Z-
dc.date.issued2008en_US
dc.identifier.citationNutrition And Cancer, 2008, v. 60 n. 4, p. 483-491en_US
dc.identifier.issn0163-5581en_US
dc.identifier.urihttp://hdl.handle.net/10722/149697-
dc.description.abstractEpigallocatechin-3-gallate (EGCG) is the major and most potent polyphenol compound of green tea that has been shown to have anticancer effects against various types of cancers. In this study, in addition to the EGCG compound, a synthetic derivative, the peracetate of EGCG (EGCG-P), was used to investigate the inhibitory effects on growth of androgen-independent prostate cancer in vivo. The advantage of EGCG-P is that it may act as a prodrug, leading to higher bioavailability than EGCG itself. The aim of our study was to compare the differences between EGCG and EGCG-P on their inhibitory effect on androgen-independent prostate cancer, CWR22R, xenograft model in nude mice. The mice were administrated daily with solvent dimethyl sulfoxide, EGCG, and EGCG-P separately through intraperitoneal injection for 20 days. Tumor volume and body weight of nude mice were recorded daily. Serum prostate-specific antigen (PSA) levels were also measured before and after the treatment. The effects of both EGCG and EGCG-P on tumor cell proliferation were assessed by immunohistochemical (IHC) method using antibodies against Ki-67 and proliferating cell nuclear antigen. The apoptotic effect was evaluated by IHC against B-cell non-Hodgkin lymphoma-2 and terminal deoxynucleotidyl transferase dUTP nick-end labeling assay by in situ apoptosis detection kit. Moreover, the potential suppression of angiogenesis by EGCG and EGCG-P on prostate cancer was examined by IHC against CD31. Our results revealed that treatment of EGCG and EGCG-P compounds suppressed the growth of CWR22R xenografts without causing any detectable side effects in nude mice. The suppression of growth of the tumor was correlated with the decrease of serum PSA level together with the reduction in tumor angiogenesis and an increase in apoptosis on prostate cancer cells. The results showed that treatment of EGCG and EGCG-P inhibited tumor growth and angiogenesis while promoting apoptosis of the prostate cancer cells in vivo. Our results suggest that EGCG-P may be a more stable and useful compound for increasing the therapeutic anticancer effects in androgen-independent prostate cancer. Copyright © 2008, Taylor & Francis Group, LLC.en_US
dc.languageengen_US
dc.publisherLawrence Erlbaum Associates, Inc. The Journal's web site is located at http://www.leaonline.com/loi/ncen_US
dc.relation.ispartofNutrition and Canceren_US
dc.rightsNutrition and Cancer. Copyright © Lawrence Erlbaum Associates, Inc.-
dc.subject.meshAcetates - Pharmacologyen_US
dc.subject.meshAndrogens - Pharmacologyen_US
dc.subject.meshAnimalsen_US
dc.subject.meshApoptosis - Drug Effectsen_US
dc.subject.meshBiological Availabilityen_US
dc.subject.meshCatechin - Analogs & Derivatives - Pharmacokinetics - Pharmacologyen_US
dc.subject.meshCell Division - Drug Effectsen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunohistochemistryen_US
dc.subject.meshKi-67 Antigen - Analysisen_US
dc.subject.meshMaleen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, Nudeen_US
dc.subject.meshNeoplasm Transplantationen_US
dc.subject.meshNeovascularization, Pathologic - Drug Therapyen_US
dc.subject.meshProdrugs - Pharmacologyen_US
dc.subject.meshProliferating Cell Nuclear Antigen - Analysisen_US
dc.subject.meshProstate-Specific Antigenen_US
dc.subject.meshProstatic Neoplasms - Blood Supply - Pathologyen_US
dc.subject.meshTea - Chemistryen_US
dc.subject.meshTransplantation, Heterologousen_US
dc.titleEffect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3- gallate on the growth of androgen-independent prostate cancer in vivoen_US
dc.typeArticleen_US
dc.identifier.emailWong, YC:ycwong@hkucc.hku.hken_US
dc.identifier.authorityWong, YC=rp00316en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1080/01635580801947674en_US
dc.identifier.pmid18584482-
dc.identifier.scopuseid_2-s2.0-46349111961en_US
dc.identifier.hkuros147787-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-46349111961&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume60en_US
dc.identifier.issue4en_US
dc.identifier.spage483en_US
dc.identifier.epage491en_US
dc.identifier.isiWOS:000257988700007-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLee, SC=24449296900en_US
dc.identifier.scopusauthoridChan, WK=36058563900en_US
dc.identifier.scopusauthoridLee, TW=8578540600en_US
dc.identifier.scopusauthoridLam, WH=26643561300en_US
dc.identifier.scopusauthoridWang, X=7501854829en_US
dc.identifier.scopusauthoridChan, TH=35291257900en_US
dc.identifier.scopusauthoridWong, YC=7403041798en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats